Financial Engines Advisors L.L.C. Takes Position in Pfizer Inc. (NYSE:PFE)

Financial Engines Advisors L.L.C. purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 14,483 shares of the biopharmaceutical company's stock, valued at approximately $384,000.

Several other large investors have also added to or reduced their stakes in PFE. United Bank increased its holdings in shares of Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company's stock worth $1,030,000 after buying an additional 1,277 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Pfizer by 67.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,801 shares of the biopharmaceutical company's stock valued at $428,000 after acquiring an additional 5,959 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in Pfizer by 7.3% during the third quarter. Loomis Sayles & Co. L P now owns 8,450 shares of the biopharmaceutical company's stock worth $245,000 after purchasing an additional 577 shares during the last quarter. FMR LLC boosted its holdings in shares of Pfizer by 3.1% in the 3rd quarter. FMR LLC now owns 14,478,489 shares of the biopharmaceutical company's stock worth $419,007,000 after purchasing an additional 435,311 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Pfizer during the 3rd quarter valued at about $1,685,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the subject of several research reports. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Finally, Bank of America restated a "neutral" rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Remove Ads

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

Pfizer Trading Up 0.8 %

Shares of NYSE:PFE traded up $0.19 on Friday, hitting $25.20. The company had a trading volume of 32,322,049 shares, compared to its average volume of 39,037,478. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm's 50-day simple moving average is $26.06 and its two-hundred day simple moving average is $26.92. The firm has a market capitalization of $142.93 billion, a price-to-earnings ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the business posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.